2025-07-15 - Analysis Report
Okay, here's a report analyzing Transmedics Group Inc. (TMDX), focusing on the provided data.

## Transmedics Group Inc. (TMDX) Stock Analysis

**Company Overview:** Transmedics Group Inc. is a medical technology company pioneering a novel approach to organ preservation for transplantation.

### 1. Performance vs. S&P 500 (VOO)

**Key Figures:**

*   **TMDX Cumulative Return:** 233.19%
*   **VOO Cumulative Return:** 67.41%
*   **Absolute Divergence (Current):** 171.4
*   **Relative Divergence:** 65.3 (Indicates TMDX's performance is in the upper range of its historical divergence from VOO)

**Analysis:** TMDX has significantly outperformed the S&P 500.  The large absolute divergence and relative divergence position suggest a strong outperformance compared to its own historical trends relative to the market.  However, the relative divergence being at 65.3 indicates there is room for further upside compared to its historical maximum divergence, but it is also a high level.

**Alpha and Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|-------|--------|------|--------|
| 2019-2021  | -4.0%  | 63.4% | -52.0% | 0.0  | 0.7    |
| 2020-2022  | 140.0% | 68.3% | 138.0% | 0.1  | 2.1    |
| 2021-2023  | 95.0%  | 69.4% | 77.0%  | 0.2  | 2.7    |
| 2022-2024  | 147.0% | 82.8% | 121.0% | 0.2  | 2.1    |
| 2023-2025  | 114.0% | 82.8% | 67.0%  | 0.5  | 4.0    |

**Analysis:** The table shows strong growth in the company's financials. CAGR and Alpha are strong which indicates growth potential, but MDD(Max Draw Down) which is the risk factor is also high.

### 2. Recent Price Action

**Key Figures:**

*   **Current Price:** \$116.88
*   **Previous Close:** \$112.46
*   **Change:** 3.93
*   **5-Day Moving Average:** \$121.23
*   **20-Day Moving Average:** \$128.56
*   **60-Day Moving Average:** \$118.37

**Analysis:** The stock price has increased significantly since the previous close. The current price is below the 5-day and 20-day moving averages, suggesting a potential short-term downward trend, but it is above the 60-day moving average, indicating a possible longer-term upward trend.  The recent price increase of 3.93 indicates some positive momentum.

### 3. Technical Indicators and Expected Return

**Key Figures:**

*   **Market Risk Indicator (MRI):** 0.3372 (Low Risk)
*   **RSI:** 38.44
*   **PPO:** -1.88
*   **Hybrid Signal:** cash_69%_Sell 0.7% of holdings (4 shares - Caution - MRI:0.35)
*   **20-Day Relative Divergence Change:** -1.1 (Negative - Short-term decline)
*   **Expected Return:** 53.3% (Over S&P 500, long-term)

**Analysis:**

*   The RSI of 38.44 is approaching oversold territory, potentially indicating a buying opportunity.
*   The negative PPO (-1.88) suggests a short-term downtrend in momentum.
*   The Hybrid Signal suggests a cautious approach, recommending a slight reduction in holdings. This aligns with the low MRI but also acknowledges potential downside risks.
*   The negative change in relative divergence indicates recent underperformance compared to the S&P 500.
*   The significant expected return of 53.3% suggests a positive long-term outlook.

### 4. Recent News & Significant Events

*   Recent business developments, regulatory changes, or market events.
*   Analyst discussions regarding recent performance and outlook.
*   Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   Market experts highlighting both risks and opportunities, advising investors to monitor news.

**Analysis:** The news indicates increased attention and volatility around TMDX, likely due to recent developments and market reactions. Investors should carefully monitor news releases and analyst reports for further insights.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 예상 EPS |
|------------|------|----------|
| 2025-05-08 | 0.7  | 0.29     |
| 2025-02-27 | 0.19 | 0.22     |
| 2024-10-28 | 0.12 | 0.29     |
| 2024-07-31 | 0.35 | 0.21     |
| 2024-04-30 | 0.35 | 0.03256  |

**Analysis:** The company has exceeded EPS expectations in most of the recent quarters, indicating strong earnings performance. The most recent quarter shows a significant beat, which could contribute to the positive price movement observed.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-03-31   | \$0.14B    | 61.47%        |
| 2024-12-31   | \$0.12B    | 59.21%        |
| 2024-09-30   | \$0.11B    | 55.94%        |
| 2024-06-30   | \$0.11B    | 60.59%        |
| 2024-03-31   | \$0.10B    | 61.91%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-03-31   | \$0.27B    | 9.64%    |
| 2024-12-31   | \$0.23B    | 3.00%    |
| 2024-09-30   | \$0.21B    | 2.01%    |
| 2024-06-30   | \$0.19B    | 6.42%    |
| 2024-03-31   | \$0.16B    | 7.65%    |

**Analysis:** The company has shown consistent revenue growth over the past five quarters. High and stable profit margins suggest efficient operations. Increasing equity and fluctuating ROE indicate varying levels of profitability relative to equity.

### 7. Overall Analysis

Transmedics Group Inc. (TMDX) presents a mixed picture. It has significantly outperformed the S&P 500, demonstrating strong earnings, revenue growth, and high-profit margins. Technical indicators suggest a potential short-term pullback but a favorable long-term outlook.  The recent news indicates increased attention and potential volatility.

**Recommendation:**

Given the high expected return and strong fundamentals, a long-term investment strategy might be appropriate. However, due to the short-term technical indicators and recent news-driven volatility, a cautious approach is warranted. Consider monitoring news and analyst reports closely and potentially staggering entry points to manage risk. The hybrid signal recommendation to slightly reduce holdings may be prudent in the short term.
